Oral glutamine supplementation reduces radiotherapyinduced esophagitis in lung cancer patients
Künye
Kanyılmaz, G., Akmansu, M., Atasever, T. ve Elbağ, Ş. (2015). Oral glutamine supplementation reduces radiotherapyinduced esophagitis in lung cancer patients. Asian Pacific Journal of Cancer Prevention, 16(1), 53-58. https://doi.org/10.7314/APJCP.2015.16.1.53Özet
Background: The purpose of this study was to assess the the efficacy of oral glutamine (GLN) in prevention of acute radiation-induced esophagitis in patients with lung cancer and determine the predictive role of clinical and dosimetric parameters. Materials and Methods: Thirty-two patients diagnosed with lung cancer were studied prospectively. Sixteen patients (50%) received prophylactic powdered GLN orally in doses of 10g/8h. Patients were treated 2 Gy per fraction daily, 5 days a week. We evaluated the grading of esophagitis daily at the end of each fraction of each treatment day until a cumulative dose of 50 Gy was reached. The primary end point was radiation-induced esophagitis. Results: All patients tolerated GLN well. Toxicity grade, weight loss, serum cytokine levels and esophageal transit times exhibited statistically significant improvement in the GLN receiving group. GLN suppressed the inflammation related to the disease and treatment and reduced toxicity with statistical significance. Conclusions: This study suggests a benefical role of oral GLN use in prevention and/or delay of radiation-induced esophagitis, in terms of esophageal transit time and serum immunological parameters, as well as weight loss.
Scopus Q Kategorisi
Q2Kaynak
Asian Pacific Journal of Cancer PreventionCilt
16Sayı
1Koleksiyonlar
- Makale Koleksiyonu [3656]
- PubMed İndeksli Yayınlar Koleksiyonu [4058]
- Scopus İndeksli Yayınlar Koleksiyonu [6298]